Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + FOLFOX4
- Development stage
- Unknown
- Lead developer
- Sun Yat-Sen Memorial Hospital
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Lenvatinib + FOLFOX4 is a combination therapy being investigated as an adjuvant treatment to prevent recurrence of hepatocellular carcinoma (HCC) in patients who have undergone liver transplantation and are beyond the Milan criteria. FOLFOX4 is a chemotherapy regimen consisting of oxaliplatin, leucovorin (folinic acid), and 5-fluorouracil (5-FU). Oxaliplatin causes DNA cross-linking, 5-FU inhibits thymidylate synthase to disrupt DNA synthesis, and leucovorin enhances the binding of 5-FU to its target. Lenvatinib is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. This combination aims to provide both systemic cytotoxic effects and targeted anti-angiogenic/anti-proliferative activity to eliminate residual micrometastases post-transplant.
- Other names
- FOLFOX4 and LenvatinibFOLFOX-4 and LenvatinibFOLFOX 4 and LenvatinibFOLFOX combined with LenvatinibFOLFOX4 + lenvatinib
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on lenvatinib + FOLFOX4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + FOLFOX4.